← Back to Medicine & Biotech
How to read this page. The written overview is an AI-generated educational summary. Papers, references, costs and companies are verify-yourself links — we do not fabricate citations, prices or company lists.
PART 1Executive Overview
1Definition

Precision oncology using liquid biopsies involves the analysis of circulating tumor DNA (ctDNA) found in a patient's blood to monitor cancer progression, detect mutations, and guide personalized treatment strategies.

Category
Medical
Best use
Early detection and personalized treatment of cancer.
Stage
NOW
2Problem It Solves

Traditional biopsy methods are often invasive, painful, and can be logistically challenging. Liquid biopsies offer a non-invasive alternative that can be performed repeatedly over time to track changes in tumor genetics, aiding in early detection, more accurate staging, and the optimization of therapeutic interventions.

3Lifecycle / Journey Stage
early commercial
PART 2Technical & Manufacturing
4How It Works

Liquid biopsies work by isolating ctDNA from a small blood sample. This ctDNA is then sequenced to identify specific genetic alterations associated with the presence or evolution of cancer. The results provide real-time insights into disease status without the need for invasive tissue sampling, enabling continuous monitoring and personalized treatment adjustments.

5Materials Used
6Manufacturing / Creation Process

Manufacturing involves developing highly sensitive and specific assays for ctDNA extraction, sequencing technologies capable of detecting low levels of ctDNA, and bioinformatics tools to interpret the vast amounts of genetic data generated. The process requires advanced laboratory equipment, skilled personnel, and stringent quality control measures.

7Build Process

The build process includes sample collection from patients, isolation of ctDNA from blood plasma, amplification and sequencing of the DNA, alignment and analysis of sequence reads against a reference genome or known cancer mutations, and interpretation of results to inform clinical decisions. This workflow is complex and requires collaboration between biologists, bioinformaticians, and clinicians.

PART 3Market & Industry
9Companies Involved
MD Anderson Cancer CenterGuardant Health

Curated names only — none are invented. Use the link to find more.

Find suppliers & makers ↗
10Estimated Costs

Cost drivers only — no verified dollar figures are shown. Check live sources for prices.

Search current prices ↗
11Case Studies

Illustrative — search real, dated examples rather than trusting a generated story.

Search case studies ↗
PART 4Academic References
12Scientific Papers / White Papers

Live searches — we don't list papers we can't verify.

Google Scholar ↗Semantic Scholar ↗PubMed ↗Crossref ↗
13Patents

Live patent searches — filings are never listed from memory.

Google Patents ↗Espacenet ↗
14Glossary
Circulating tumor DNA (ctDNA)
Fragmented DNA released by dying cancer cells into the bloodstream, used for non-invasive monitoring of cancer.
Next-generation sequencing (NGS)
Advanced DNA sequencing technologies capable of rapid and accurate determination of genetic sequences from small sample volumes.
Bioinformatics
The application of computer science, statistics, and other computational methods to analyze biological data, particularly genomic information.
15References

Verify against primary sources only.

Google Scholar ↗Crossref ↗Wikipedia ↗
Related Technologies

Source: curated technology intelligence stream with tracked references.